Manish Bais, DVM, PhD
Research Associate Professor
Boston University Henry M. Goldman School of Dental Medicine
Dept of Molecular & Cell Biology

PhD, Indian Veterinary Research Institute (IVRI)
DVM, Nagpur Veterinary College
MVSc, Indian Veterinary Research Institute (IVRI)



Dr. Manish Bais is a Research Assistant Professor in the Department of Molecular and Cell Biology at Boston University’s Henry M. Goldman School of Dental Medicine. Dr. Bais is also an important member of the Oral Cancer Research Initiative (OCRI). With funding from the OCRI, Dr. Bais travelled to the National Institute of Dental and Craniofacial Research in the summer of 2013 to receive mouse model training in the lab of Dr. Roberto Weigert. Dr. Bais has made large contributions to the initiative with the development of an orthotropic oral cancer mouse model.

The orthotropic nude mouse models of non-metastatic and metastatic tongue cancer that Dr. Bais has developed will facilitate mechanistic in vivo studies and preclinical testing of novel targets for anti-oral cancer therapy. Specifically, he has generated mice with non-metastatic tongue tumors following injection of human tongue squamous cell carcinoma (OSCC) CAL27 cells into tongues of nude mice. In addition, Dr. Bais has generated mice with tongue tumors formed by injection of SCC2 cells that metastasize to lung, bone and liver, sites of metastases of human tongue cancers.

Dr. Bais is collaborating with many OCRI investigators including Dr. Maria Kukuruzinska, Dr. Philip Trackman, Dr. Bob Varelas and Dr. David Sherr. This animal model and other models still in progress can help us to better understand the biology of oral cancer as well as provide new therapeutic opportunities in the treatment of this deadly disease.

2015-2017 RO3- NIH/ NIDCR: LOXL2 in TMJ osteoarthritis
2015-2016 Henry M. Goldman School of Dental Medicine: Lysine specific demethylase 1 inhibitor for improved personalized oral cancer therapy
2014-2015 CNN Pilot grant, Center for Nanoscience and Nanotechnology (CNN), Boston University: Nanodelivery Approaches for Targeting DPAGT1 and LSD1 for oral Squamous Cell Carcinoma therapy
2014-2015 CTSI, BUSDM: Patient-derived Tumors Orthotopic Oral Cancer Mouse Models
2012-2013 BUSDM seed funding: LOXL2 in Anabolic Response to TMJ-Osteoarthritis


LOXL2 in Temporomandibular Joint Osteoarthritis
08/01/2015 - 07/31/2018 (PI)
NIH/National Institute of Dental & Craniofacial Research
5R03DE025274-02




Yr Title Project-Sub Proj Pubs
2016 LOXL2 in Temporomandibular Joint Osteoarthritis 5R03DE025274-02
2015 LOXL2 in Temporomandibular Joint Osteoarthritis 1R03DE025274-01
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, Lee J, Pai SI, Varelas X, Egloff AM, Snyder-Cappione JE, Belkina AC, Bais MV, Monti S, Kukuruzinska MA. Functional and genomic analyses reveal therapeutic potential of targeting ß-catenin/CBP activity in head and neck cancer. Genome Med. 2018 07 20; 10(1):54.View Related Profiles. PMID: 30029671.
     
  2. Bais MV. Targeting oral cancer epigenome via LSD1. Aging (Albany NY). 2017 Dec 11; 9(12):2455-2456. PMID: 29232656.
     
  3. Trackman PC, Bais MV. Measurement of lysyl oxidase activity from small tissue samples and cell cultures. Methods Cell Biol. 2018; 143:147-156.View Related Profiles. PMID: 29310775.
     
  4. Bais MV, Goldring MB. LOXL2 as a protective in osteoarthritis cartilage. Aging (Albany NY). 2017 Oct 27; 9(10):2024-2025. PMID: 29080554.
     
  5. Alshenibr W, Tashkandi MM, Alsaqer SF, Alkheriji Y, Wise A, Fulzele S, Mehra P, Goldring MB, Gerstenfeld LC, Bais MV. Anabolic role of lysyl oxidase like-2 in cartilage of knee and temporomandibular joints with osteoarthritis. Arthritis Res Ther. 2017 Aug 02; 19(1):179.View Related Profiles. PMID: 28764769.
     
  6. Alsaqer SF, Tashkandi MM, Kartha VK, Yang YT, Alkheriji Y, Salama A, Varelas X, Kukuruzinska M, Monti S, Bais MV. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget. 2017 Sep 26; 8(43):73372-73386.View Related Profiles. PMID: 29088714.
     
  7. Bais MV, Kukuruzinska M, Trackman PC. Corrigendum to "Orthotopic non-metastatic and metastatic oral cancer mouse models" [Oral Oncol. 51(5) (2015) 476-482]. Oral Oncol. 2017 09; 72:201.View Related Profiles. PMID: 28743466.
     
  8. Trackman PC, Saxena D, Bais MV. TGF-ß1- and CCN2-Stimulated Sirius Red Assay for Collagen Accumulation in Cultured Cells. Methods Mol Biol. 2017; 1489:481-485.View Related Profiles. PMID: 27734398.
     
  9. Stanford EA, Ramirez-Cardenas A, Wang Z, Novikov O, Alamoud K, Koutrakis P, Mizgerd JP, Genco CA, Kukuruzinska M, Monti S, Bais MV, Sherr DH. Role for the Aryl Hydrocarbon Receptor and Diverse Ligands in Oral Squamous Cell Carcinoma Migration and Tumorigenesis. Mol Cancer Res. 2016 Aug; 14(8):696-706.View Related Profiles. PMID: 27130942; PMCID: PMC4987205; DOI: 10.1158/1541-7786.MCR-16-0069;.
     
  10. Alsulaiman M, Bais MV, Trackman PC. Lysyl oxidase propeptide stimulates osteoblast and osteoclast differentiation and enhances PC3 and DU145 prostate cancer cell effects on bone in vivo. J Cell Commun Signal. 2016 Mar; 10(1):17-31.View Related Profiles. PMID: 26627907; DOI: 10.1007/s12079-015-0311-9;.
     
Showing 10 of 29 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 29 publications over 14 distinct years, with a maximum of 7 publications in 2017

YearPublications
20032
20041
20071
20081
20093
20101
20111
20121
20132
20143
20154
20161
20177
20181
Contact for Mentoring:


700 Albany St Ctr for Adv Biomed Res
Boston MA 02118
Google Map


Bais's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department